• Channels
    • All News
    • Premium Content
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Bust­ed in the wake of a CRL, Athenex brings out bud­get axe af­ter 'go­ing con­cern' alert

Last year
Deals

Apel­lis ris­es on long-term da­ta for Soliris chal­lenger af­ter mixed PhI­II read­out, and an­a­lysts are more bull­ish on ap­proval

Last year
R&D

A lit­tle biotech crows about its Covid-19 'one and done' PhI­II, caus­ing at least one top an­a­lyst to change his tune as shares soar

Last year
R&D
Coronavirus

Al­ny­lam seeks com­pen­sa­tion from Mod­er­na and Pfiz­er in suits over patent­ed de­liv­ery of their Covid-19 vac­cines

Last year
Coronavirus
Law

Bio­gen los­es an­oth­er bid to re­vive Tec­fidera patent as gener­ic keeps eat­ing in­to block­buster sales

Last year
Pharma
Law

As­traZeneca shells out $775M to set­tle Ul­tomiris patent suit with Roche

Last year
Pharma
Law

J&J's Alex Gorsky bagged $26M in pay and perks for 2021, land­ing near the top of the Big Phar­ma CEO lad­der

Last year
People
Pharma

Pub­li­cis brings back its Health­Front deal­mak­ing mar­ket­place for phar­ma and health­care ad­ver­tis­ers

Last year
Pharma
Marketing

Phar­ma in­dus­try rep­u­ta­tion con­tin­ues to slide, ac­cord­ing to new Har­ris Poll. But how low can it go?

Last year
Pharma
Marketing

Sanofi part­ners up with dom­i­nant ADC play­er Seagen, dou­bling down on on­col­o­gy in hunt for a bet­ter pipeline

Last year
Deals
R&D

With its share price chewed to pieces, Nick Leschly's 2sev­en­ty scores $170M to help weath­er the storm

Last year
Financing
Bioregnum

Bio­gen fi­nal­ly pub­lish­es PhI­II re­sults for Aduhelm as crit­ics chas­tise low-rank­ing jour­nal, ‘gen­tle and un­re­veal­ing’ peer re­view

Last year
Pharma

With new RSV an­ti­body, Sanofi looks to avoid a re­peat of a 20-year-old pric­ing con­tro­ver­sy

Last year
R&D
Pharma

Back to the fun­da­men­tals: Fra­zier rolls out $1B fund to ramp up a new slate of biotech star­tups

Last year
Financing

Biotech founders sen­tenced to 1 year and 1 day for steal­ing Genen­tech se­crets, ly­ing to in­vestors

Last year
People
Law

Mar­ket­ingRx roundup: Pfiz­er’s CEO talks pan­dem­ic pres­sure at SXSW; Ex­act Sci­ences teams with Katie Couric for screen­ing

Last year
Pharma
Marketing

Pushed out of Eli Lil­ly in ethics scan­dal, Josh Smi­ley lands a top job at Zai Lab

Last year
People

Mer­ck suf­fers rare Keytru­da set­back as the block­buster fails a PhI­II prostate can­cer test with Lyn­parza

Last year
R&D

No­vo Nordisk, Gates Foun­da­tion pledge $90M to fund an­tivi­ral re­search for the next pan­dem­ic

Last year
R&D
Discovery

Root­ing for a come-from-be­hind win, Black­stone in­fus­es $330M in­to Sanofi's CD38 de­vel­op­ment plan

Last year
R&D

Ei­sai finds an ex­it from Aduhelm, with small roy­al­ties if it ever nabs cov­er­age

Last year
Pharma

FDA or­ders In­cyte to hold up yet again in the hunt for block­buster fran­chise

Last year
FDA+

Nek­tar crushed — again — as Bris­tol My­ers al­ly runs in­to PhI­II melanoma fail

Last year
R&D

FDA hits back Fasen­ra in key rhi­nos­i­nusi­tis field, putting As­traZeneca even fur­ther be­hind Big Phar­ma ri­vals

Last year
Pharma
FDA+
First page Previous page 109110111112113114115 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Premium Content
  • Don't Miss
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2023

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

e-mail

password

Endpoints News

request magic link

If you're already an Endpoints subscriber, enter your email below for a magic link that lets you log in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.

email

Endpoints News

reset password

We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.

email

Endpoints News

About You

Subscriptions

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 2 PM ET

ENDPOINTS MARKETING RX Tue at 2 PM ET

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET